Neuren Pharmaceuticals Ltd has released a press release.
Disclosure under Listing Rule 4.3D
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- S&P DJ Indices Announces March Quarterly Rebalance
- Preliminary Final Report
- Neuren announces new US patent to be granted for NNZ-2591
- Consolidation/Split - NEU
- Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
Later from Neuren Pharmaceuticals
- First patent in Japan granted for Neurens trofinetide
- Neuren announces investment and exclusive negotiation period
- Announcement of buy-back - Appendix 3C
- Neuren and ACADIA announce agreement for North America
- Neuren receives initial payment of US$10 million from ACADIA
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals